Skip to main content

Table 4 Adjusted estimated marginal mean EORTC QLQ-C15-PAL post-treatment scores

From: Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide

Scales

Mean (95% CI)

Octreotide (N = 52)

Placebo (N = 54)

Mean difference (95% CI)

P-value

Overall HrQoLa

35.31 (21.68, 48.94)

34.86 (21.30, 48.41)

0.45 (−10.35, 11.26)

0.935

Physical functioninga

33.97 (21.30, 46.64)

31.01 (20.31, 41.69)

2.97 (−6.52, 12.46)

0.539

Emotional functioninga

60.30 (45.18, 75.42)

58.95 (46.22, 71.67)

1.36 (−10.40, 13.12)

0.821

Fatigueb

73.58 (60.28, 86.87)

72.88 (59.75, 86.00)

0.70 (−10.07, 11.46)

0.899

Nausea & vomitingb

51.45 (33.98, 68.91)

47.79 (32.39, 63.18)

3.66 (−10.35, 17.68)

0.608

Painb

56.38 (40.27, 72.49)

55.53 (42.61, 68.44)

0.85 (− 11.08, 12.79)

0.888

Dyspnoeab

31.67 (17.77, 45.54)

29.76 (17.00, 42.53)

1.89 (−9.69, 13.48)

0.748

Insomniab

41.00 (26.17, 55.84)

48.14 (34.14, 62.14)

− 7.14 (− 20.88, 6.61)

0.308

Appetite lossb

52.10 (34.34, 69.87)

52.09 (34.90, 69.28)

0.16 (−14.23, 14.26)

0.998

Constipationb

49.45 (32.91, 65.99)

51.47 (37.22, 65.72)

−2.02 (−16.22, 12.19)

0.780

  1. HrQoL Health related quality of life
  2. ahigher scores represent better outcomes
  3. bhigher scores represent greater symptom burden